Posted on 4月 21, 20234/21/23
Left-Right-Left: The Latest in Pharma-Payer Ping Pong
Posted on 4月 17, 20234/17/23
What EVERSANA’s Growing Abstract Count at ISPOR U.S. Means to the HEOR Industry
Posted on 3月 9, 20233/9/23
The Pitfalls of Government Price Setting: Value Assessments in the U.S. vs. Germany
Posted on 2月 23, 20232/23/23
The State of National Healthcare Policy and Pricing Webinar 2023
Posted on 10月 12, 202210/12/22
The Evolution of HTA and Its Impact on Drug Prices in Japan
Posted on 3月 23, 20223/23/22
How Do We Pay for a Cure? How to Put a Price on Life-changing Treatments
Posted on 12月 22, 202112/22/21
Why Launching in Europe Is Unlike Launching Anywhere Else
Posted on 12月 20, 202112/20/21
Aligning Net Pricing with Patient Outcomes – Removing Barriers to Value-Based Contracting
Posted on 12月 1, 202112/1/21
BLOG: Segmenting Health Systems
Posted on 11月 15, 202111/15/21